Journal
CANCER LETTERS
Volume 454, Issue -, Pages 191-203Publisher
ELSEVIER IRELAND LTD
DOI: 10.1016/j.canlet.2019.04.017
Keywords
Cancer immunotherapy; Immunogenic chemotherapy; Immunogenic cell death; Combined strategy; Chemo-immunotherapy
Categories
Funding
- National Natural Science Foundation of China [81803442, 81703425]
Ask authors/readers for more resources
Cancer immunotherapy holds great potential to battle cancer by exerting a durable immunity effect. However, this process might be limited by various constraints existing in the tumor microenvironment (TME), such as the lack of available neoantigen, insufficient T cells from the naive repertoire, or immunosuppressive networks in which immunogenic tissue is protected from immune attacks. Certain chemotherapeutic drugs could elicit immune-potentiating effects by either inducing immunogenicity or relieving tumor-induced immunosuppression. Some also leave tumors directly susceptible to cytotoxic T cell attacks. Mounting evidence accumulated from preclinical and clinical studies suggests that these two treatment modalities might be mutually reinforcing as an effective chemo-immunotherapy strategy. Herein, we reviewed the latest advances in cancer immunotherapy and related mechanisms involved in chemotherapeutic-mediated immune activation. The emerging combination strategies and synergistic effects in response to chemo-immunotherapy are highlighted. We also discuss the challenges and critical considerations in its future development.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available